ライフサイエンスコーパス: PCI

1 PCI followed by TAVR in the same session had similar out

2 PCI of lesions with reduced fractional flow reserve impr

3 PCI was well tolerated, improved symptoms, and resulted

4 PCI, compared with CABG, was associated with a similar r

5 - (50 to 100 PCIs per year), and high- (>100 PCIs per year) volume groups, and determined the adjuste

6 <50 PCIs per year), intermediate- (50 to 100 PCIs per year), and high- (>100 PCIs per year) volume gr

7 ime from 152 684 consecutive CAs and 103 177 PCIs performed between 2009 and 2013 were analyzed.

8 rator was 59; 44% of operators performed <50 PCI procedures per year.

9 We divided operators into low- (<50 PCIs per year), intermediate- (50 to 100 PCIs per year),

10 Physicians who performed more than 50 PCIs per year were the main exposure variable of interes

11 nticoagulant use were examined among 553 562 PCIs performed by 9254 operators at 1538 hospitals for n

12 period, 309 CPs were recorded during 59 644 PCI-CABG procedures with the incidence rising from 0.32%

13 Direct transport to a PCI center is associated with better outcomes for out-of

14 cts still remain to be addressed: What about PCI or CABG with a low versus a high score respectively?

15 And what about PCI with a low score versus CABG with a high score?

16 After PCI, TAVR was postponed in 2 patients (0.3%).

17 with patients' risk of developing AKI after PCI.

18 ce of AKI among Medicare beneficiaries after PCI from 2004 to 2009 and subsequent post-discharge adve

19 f unplanned readmission within 30 days after PCI compared with insured patients.

20 patients who had received Mynx devices after PCI procedures with femoral access from January 1, 2011,

21 sociated with less dyspnea improvement after PCI.

22 s in women and minorities vs white men after PCI with everolimus-eluting stents.

23 tent thrombosis in the first 12 months after PCI (3.9% vs. 2.4%; p < 0.001).

24 survival to liver transplant (3 months after PCI).

25 ee of cardiovascular symptoms 3 months after PCI.

26 ferral at discharge was less prevalent after PCI than cardiac surgery.

27 ion in cardiac rehabilitation referral after PCI, coronary artery bypass surgery, and valve surgery.

28 al should focus on increasing referral after PCI, especially in low referral hospitals.

29 d variations in the utilization of SDD after PCI during the contemporary era.

30 dest increase in the proportion of SDD after PCI from 2.5% in 2009 to 7.4% in 2013 (P-trend <0.001).

31 the patterns of cardiac stress testing after PCI in the single-payer Canadian healthcare system, wher

32 dations against routine stress testing after PCI.

33 likely to benefit from stress testing after PCI.

34 sk of angina was similar over the year after PCI in patients with versus without DM (relative risk, 1

35 ts, particularly within the first year after PCI.

36 METHODS AND Data were analyzed on all PCI-CABG procedures performed in England and Wales betwe

37 y (314 [35.0%] vs 925 [60.8%]; P < .001) and PCI (265 [29.5%] vs 707 [46.5%]; P < .001) were more com

38 confidence interval, 0.61-0.72; P<0.001) and PCI (hazard ratio, 0.73; 95% confidence interval, 0.62-0

39 fusion, and postfibrinolysis angiography and PCI.

40 in patient radiation exposure during CA and PCI was noted between 2009 and 2013.

41 patients' exposure to radiation from CA and PCI.

42 s independent of patient-related factors and PCI procedure complexity.

43 t primary care clinics, small hospitals, and PCI hospitals in the southern state of Tamil Nadu in Ind

44 Patients undergoing TAVR and PCI in the same session had similar rate of the composit

45 led trials comparing manual thrombectomy and PCI alone in patients with ST-segment-elevation myocardi

46 t prospectively collects data on all CAs and PCIs performed in the 36 catheterization laboratories in

47 ined the adjusted association between annual PCI volume and in-hospital outcomes, including mortality

48 and practiced at hospitals with lower annual PCI volumes.

49 March 31, 2015, we examined operator annual PCI volume.

50 os, there were higher numbers of appropriate PCIs per year in the period from 2012 to 2014.

51 Changes in the number of appropriate PCIs were also assessed.

52 nt randomisation, with 105 patients assigned PCI and 95 assigned the placebo procedure.

53 Differences between PCI and CABG were assessed using longitudinal random-eff

54 were no significant QoL differences between PCI and CABG.

55 rding to low to intermediate Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (rando

56 during UFH PCIs and 12.0% during bivalirudin PCIs.

57 Among selected patients with LMCAD, both PCI and CABG result in similar QoL improvement through 3

58 nt elevation myocardial infarction (group by PCI or ST-segment elevation myocardial infarction intera

59 al to Demonstrate the Efficacy of Cangrelor [PCI]: NCT00305162; Cangrelor Versus Standard Therapy to

60 METHODS AND CHAMPION PCI (A Clinical Trial to Demonstrate the Efficacy of Can

61 Management of Platelet Inhibition (CHAMPION PCI, CHAMPION PLATFORM, and CHAMPION PHOENIX) trials of

62 s and 5850 patients (1157 MV-PCI and 4693 CO-PCI).

63 (MV-PCI) versus culprit vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-segment-el

64 n short-term mortality with MV-PCI versus CO-PCI (odds ratio [OR], 1.08; 95% confidence interval [CI]

65 3; P=0.57) with MV-PCI when compared with CO-PCI.

66 it with single-stage MV-PCI compared with CO-PCI.

67 ography for Multivessel Evaluation) compared PCI guided by fractional flow reserve with best MT in pa

68 y at arrival were randomized to conventional PCI or postconditioning.

69 % reported less dyspnea at 1 month after CTO PCI.

70 reported less dyspnea improvement after CTO PCI.

71 pnea Scale at baseline and 1 month after CTO PCI.

72 improvement among patients selected for CTO PCI.

73 Successful CTO PCI was associated with more frequent dyspnea improvemen

74 rienced centers, 987 patients undergoing CTO PCI (procedure success 82%) were assessed for dyspnea wi

75 common symptom among patients undergoing CTO PCI and improves significantly with successful PCI.

76 otal of 376 CP were recorded from 26 807 CTO-PCI interventions (incidence of 1.40%) with an increase

77 lar Intervention Society data set on all CTO-PCI procedures performed in England and Wales between 20

78 coronary intervention for stable angina (CTO-PCI) is a rare but serious event.

79 e, predictors, and outcomes of CP during CTO-PCI were defined.

80 he long-term quality-of-life benefits of DES-PCI versus CABG for patients with 3-vessel or left main

81 essel or left main CAD to either CABG or DES-PCI.

82 t 5-year follow-up, CABG was superior to DES-PCI on several SAQ domains including angina frequency an

83 Routine thrombus aspiration during PCI for ST-segment-elevation myocardial infarction did n

84 fits and risks of thrombus aspiration during PCI in patients with ST-segment-elevation myocardial inf

85 dence, predictors, and outcomes of CP during PCI-CABG were defined.

86 ned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of r

87 Among 1080 elective PCI patients (mean age, 65 years; 74.7% men), 34.0% had

88 re and at 1, 6, and 12 months after elective PCI with the Seattle Angina Questionnaire angina frequen

89 9; 95% CI, 0.93-1.05; P = .66), and elective PCI (OR, 0.93; 95% CI, 0.84-1.03; P = .17).

90 from 73 [41-125] to 55 [31-91] Gy cm(2) for PCI (P<0.0001).

91 includes the use of radial-artery access for PCI and administration of potent P2Y12 inhibitors withou

92 CI Registry to identify in-hospital care for PCI in the United States.

93 The incremental cost-effectiveness ratio for PCI compared with MT was $17 300 per quality-adjusted li

94 ensitiser, chlorin e6, can be repurposed for PCI by conjugating the chlorin to a cell penetrating pep

95 In graft PCI, predictors of perforation were history of stroke, N

96 t of exercise time increment between groups (PCI minus placebo 16.6 s, 95% CI -8.9 to 42.0, p=0.200).

97 Interventions/Intravascular imaging-guided PCI of the proximal right coronary artery and the left m

98 Among the readmitted patients, 13% had PCI, 2% had coronary artery bypass surgery, and 3% died

99 enosis on selective coronary angiography had PCI.

100 ere stratified according to whether they had PCI of an SVG or a non-SVG lesion.

101 rger hospitals, teaching hospitals, and high PCI volume hospitals had higher utilization of SDD compa

102 ith invasive coronary angiography and ad hoc PCI during TAVR is feasible and was not associated with

103 n [FACT-COG] perceived cognitive impairment [PCI] subscale): difference between groups after interven

104 es in and around the scissile P1-P1' bond in PCI and alpha1AT, resulting in serpins with the desired

105 The percentage of inappropriate PCIs for all patients dropped from 18.2% in 2010 to 10.6

106 time in the number and rate of inappropriate PCIs.

107 722 US hospitals was used to identify index PCI cases in patients >/=18 years old.

108 s of the serpin family: protein C inhibitor (PCI) and alpha1-antitrypsin (alpha1AT); however, both ex

109 Inpatient PCI.

110 he outcomes and temporal trends of inpatient PCI at centers without on-site cardiac surgery in an uns

111 In a national sample of inpatient PCI cases, 30-day readmissions were associated with a si

112 Of the 6912232 inpatient PCIs performed, 2336334 patients (33.8%) were women and

113 dergoing percutaneous coronary intervention (PCI) according to current practice, which includes the u

114 fter CTO percutaneous coronary intervention (PCI) are unknown.

115 T) after percutaneous coronary intervention (PCI) based on the presence or absence of anatomically-co

116 CABG) or percutaneous coronary intervention (PCI) carries benefits or risks in this group of stable p

117 primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STE

118 n during percutaneous coronary intervention (PCI) for the treatment of ST-segment-elevation myocardia

119 ent with percutaneous coronary intervention (PCI) has not been well established.

120 ery over percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary arte

121 goal of percutaneous coronary intervention (PCI) in stable angina and is commonly observed clinicall

122 d during percutaneous coronary intervention (PCI) in the United States for patients with non-ST-segme

123 ted with percutaneous coronary intervention (PCI) in the Veterans Affairs (VA) health system are not

124 primary percutaneous coronary intervention (PCI) induced by repetitive interruptions of blood flow t

125 Primary percutaneous coronary intervention (PCI) may therefore be less beneficial in patients with Q

126 Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) has historically be

127 ns after percutaneous coronary intervention (PCI) on healthcare costs has not been well studied.

128 rting of percutaneous coronary intervention (PCI) outcomes may create disincentives for physicians to

129 ge of 50 percutaneous coronary intervention (PCI) procedures performed annually by each operator.

130 is after percutaneous coronary intervention (PCI) remains uncertain, with some studies finding in fav

131 rs after percutaneous coronary intervention (PCI) to be rarely appropriate, unless prompted by sympto

132 e use of percutaneous coronary intervention (PCI) to restore blood flow in an infarct-related coronar

133 CABG) or percutaneous coronary intervention (PCI) using everolimus-eluting stents.

134 tting if percutaneous coronary intervention (PCI) was uncomplicated; otherwise TAVR was postponed.

135 ly after percutaneous coronary intervention (PCI) with drug-eluting stent placement has not been pros

136 eness of percutaneous coronary intervention (PCI) with drug-eluting stents (DES) versus bare metal st

137 red with percutaneous coronary intervention (PCI) with drug-eluting stents (DES), improvements driven

138 est that percutaneous coronary intervention (PCI) with drug-eluting stents may be an acceptable alter

139 y (LMCA) percutaneous coronary intervention (PCI), but the overall picture remains inconclusive and w

140 such as percutaneous coronary intervention (PCI), can influence physicians to avoid high-risk patien

141 dergoing percutaneous coronary intervention (PCI), coronary artery bypass surgery, or valve surgery b

142 igh-risk percutaneous coronary intervention (PCI), particularly in those with severely reduced left v

143 D) after percutaneous coronary intervention (PCI), uptake of this program has been relatively poor in

144 ts after percutaneous coronary intervention (PCI).

145 PT after percutaneous coronary intervention (PCI).

146 rgery or percutaneous coronary intervention (PCI).

147 emporary percutaneous coronary intervention (PCI).

148 primary coronary percutaneous intervention (PCI), and norepinephrine dose, the mean +/- SD post-arri

149 Require Percutaneous Coronary Intervention [PCI] [CHAMPION PHOENIX] [CHAMPION]: NCT01156571).

150 complex percutaneous coronary interventions (PCIs) has increased in the last few years, with a growin

151 cacy of percutaneous coronary interventions (PCIs).

152 measured by GC-positive chemical ionization (PCI)-MS/MS.

153 35 spoke health care centers to the 4 large PCI hub hospitals and leveraged recent developments in p

154 tivity (HPR) in SVG PCI versus native lesion PCI is unknown.

155 AND Patients who underwent unprotected LMCA PCI between 2005 and 2014 because of stable coronary art

156 come in patients undergoing unprotected LMCA PCI in a Swedish nationwide observational study.

157 ible hazard when performing unprotected LMCA PCI without IVUS guidance.

158 ome benefit when performing unprotected LMCA PCI.

159 Many PCI operators in the United States are performing fewer

160 At 1 month, PCI was associated with better QoL than CABG.

161 te myocardial infarction and performing more PCIs than nonoutlier hospitals (P<0.05 for each).

162 ng those who underwent immediate multivessel PCI.

163 the 341 patients (55.4%) in the multivessel PCI group (relative risk, 0.83; 95% confidence interval

164 y PCI group as compared with the multivessel PCI group was 0.84 (95% CI, 0.72 to 0.98; P=0.03), and t

165 andomized studies and 5850 patients (1157 MV-PCI and 4693 CO-PCI).

166 essel percutaneous coronary intervention (MV-PCI) versus culprit vessel-only PCI (CO-PCI) in patients

167 rials are needed to determine the role of MV-PCI in this setting.

168 no significant benefit with single-stage MV-PCI compared with CO-PCI.

169 t difference in short-term mortality with MV-PCI versus CO-PCI (odds ratio [OR], 1.08; 95% confidence

170 OR, 1.47; 95% CI, 0.39-5.63; P=0.57) with MV-PCI when compared with CO-PCI.

171 Using a national PCI database, the incidence, predictors, and outcomes of

172 Using a national PCI database, the incidence, predictors, and outcomes of

173 stering of county, transport time to nearest PCI center, initial heart rhythm, and prehospital ECG in

174 d hospitals that were recognized as negative PCI outliers in 2 states (Massachusetts and New York) fr

175 of whom 873 (57.9%) bypassed the nearest non-PCI hospital and 148 (9.8%) were transported to non-PCI

176 Compared with patients taken to non-PCI hospitals, odds of survival were higher for patients

177 pital and 148 (9.8%) were transported to non-PCI hospitals.

178 patients undergoing elective or nonelective PCI.

179 rehabilitation program explained only 10% of PCI variation and 0% of cardiac surgery variation.

180 The likelihood of PCI at outlier (relative risk [RR], 1.13; 95% confidence

181 forming fewer than the recommended number of PCI procedures annually.

182 rease has occurred for a large proportion of PCI hospitals.

183 high-risk patients from public reporting of PCI outcomes in NYS has influenced physician attitudes,

184 To compare the long-term safety of PCI with drug-eluting stent vs CABG in patients with LMC

185 s a blinded, multicentre randomised trial of PCI versus a placebo procedure for angina relief that wa

186 The use of PCI in non-infarct-related coronary arteries remains con

187 rgo cardiac stress testing within 2 years of PCI, with one third undergoing repeat stress tests.

188 The total number of PCIs in patients with no acute coronary syndrome/no prio

189 a significant increase in the proportion of PCIs at centers without on-site cardiac surgery within t

190 patients (45.9%) in the culprit-lesion-only PCI group and in 189 of the 341 patients (55.4%) in the

191 ive risk of death in the culprit-lesion-only PCI group as compared with the multivessel PCI group was

192 rvention (MV-PCI) versus culprit vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-se

193 The risk of MACCE with CABG or PCI was compared using multivariable adjustment and a pr

194 late (31-day to 5-year) benefit of CABG over PCI no longer varied by acuity of presentation, with a h

195 porting has made them more likely to perform PCI for these subgroups.

196 istry of all nonfederal hospitals performing PCI and cardiac surgery in Washington State.

197 Post-PCI AKI is associated with increased risk of death, myoc

198 Post-PCI FFR of 0.92 was found to have the highest diagnostic

199 Post-PCI FFR was significantly lower in vessels with vessel-o

200 No volume relationship was observed for post-PCI bleeding.

201 l patients of FAME 1 and FAME 2 who had post-PCI FFR measurement were included.

202 r hospital discharge in patients having post-PCI AKI is poorly defined, and the relationship between

203 A higher post-PCI FFR value is associated with a better vessel-related

204 We investigated the potential of post-PCI FFR measurements to predict clinical outcome in pati

205 outcome of lower and upper tertiles of post-PCI FFR significant difference was found favoring upper

206 ze and mitigate potentially preventable post-PCI readmissions.

207 tions performed within 45 days after primary PCI were not counted as events in the group receiving PC

208 After primary PCI, the ADIR and ADBR both markedly decreased over time

209 e frequently performed emergency and primary PCI procedures and practiced at hospitals with lower ann

210 HODS AND The ECG was assessed before primary PCI for the presence of QW (early) in 515 STEMI patients

211 s (11.2%) who underwent conventional primary PCI and in 65 (10.5%) who underwent postconditioning (ha

212 ndomly allocated 1:1 to conventional primary PCI, including stent implantation, or postconditioning p

213 ine ischemic postconditioning during primary PCI failed to reduce the composite outcome of death from

214 For primary PCI, there was also no evidence for increased or decreas

215 Thus, to clarify the benefit from primary PCI in STEMI patients with QW, we examined the associati

216 patients with QW still benefit from primary PCI.

217 AND In the DANAMI-3-PRIMULTI study (Primary PCI in Patients With ST-Elevation Myocardial Infarction

218 ultivessel disease who had undergone primary PCI of an infarct-related coronary artery in a 1:2 ratio

219 nd multivessel disease who underwent primary PCI of an infarct-related artery, the addition of FFR-gu

220 nting in STEMI patients treated with primary PCI.

221 d MVO in STEMI patients treated with primary PCI.

222 not counted as events in the group receiving PCI for an infarct-related coronary artery only.

223 n the world with a nationally representative PCI registry.

224 ring different methods of revascularization (PCI or CABG) against each other or medical treatment in

225 ce (pLVAD) on renal function after high-risk PCI remains unknown.

226 Microaxial pLVAD support during high-risk PCI was independently associated with a significant redu

227 orted matched-controls) undergoing high-risk PCI with ejection fraction </=35%.

228 pport protected against AKI during high-risk PCI.

229 performed a secondary analysis of the RIVER-PCI (Ranolazine in Patients with Incomplete Revasculariz

230 treated angina and severe coronary stenosis, PCI did not increase exercise time by more than the effe

231 I and improves significantly with successful PCI.

232 SVG PCI is associated with a considerably higher risk of 2-y

233 SVG PCI was independently associated with a higher 2-year ri

234 udied ischemic and bleeding events after SVG PCI and their association with HPR.

235 statistical interaction between HPR and SVG PCI in regard to major adverse cardiac events (adjusted

236 82 subjects in ADAPT-DES, 405 (4.7%) had SVG PCI.

237 nce of high platelet reactivity (HPR) in SVG PCI versus native lesion PCI is unknown.

238 R conferring similar risk in SVG and non-SVG PCI.

239 ay be beneficial for patients undergoing SVG PCI.

240 atients with severe CAD left untreated (TAVR+PCI: 10.4%; severe CAD left untreated: 15.4%; no-CAD: 14

241 Here we show that PCI domain-containing protein 2 (Pcid2) is highly expres

242 esults of EXCEL, these findings suggest that PCI and CABG provide similar intermediate-term outcomes

243 Mean initial costs were higher in the PCI group ($9944 versus $4440; P<0.001) but by 3 years w

244 ial infarction were numerically lower in the PCI group (8.3% versus 10.4%; P=0.28).

245 Angina was significantly less severe in the PCI group at all follow-up points to 3 years.

246 of patients in the CABG group and 45% in the PCI group died.

247 tratum (26.1% vs. 29.9%, p = 0.41) or in the PCI stratum (17.8% vs. 19.2%, p = 0.84).

248 (15.3% vs. 30.3%, p = 0.02), but not in the PCI stratum (35.6% vs. 26.5%, p = 0.12).

249 /high SYNTAX scores compared with 13% in the PCI stratum (p < 0.001).

250 Of these PCIs, 396741 (5.7%) were conducted at centers without on

251 ficant after adjustment on Fluoroscopy time, PCI procedure complexity, change of x-ray equipment, and

252 ination hospital was classified according to PCI center status (catheterization laboratory immediatel

253 d for patients bypassing closer hospitals to PCI centers (odds ratio, 3.02; 95% confidence interval,

254 iration and 262 of 9151 (2.9%) randomized to PCI alone (hazard ratio, 0.84; 95% confidence interval,

255 f 510 patients with STEMI were randomized to PCI with deferred versus immediate stent implantation.

256 rvival was higher among those transported to PCI centers (33.5% versus 14.6%; adjusted odds ratio, 2.

257 irculation, 1359 (90.2%) were transported to PCI centers, of whom 873 (57.9%) bypassed the nearest no

258 Appropriate use criteria were applied to PCIs performed in New York in patients without acute cor

259 th bivalirudin were largest for transfemoral PCI (GPI-adjusted risk difference, -1.11%; 95% CI: -1.43

260 largest among those undergoing transfemoral PCI, whereas no bleeding benefit was observed for those

261 .43%, -0.80%) and negligible for transradial PCI (GPI-adjusted risk difference, 0.09%; 95% CI: -0.32%

262 observed for those treated with transradial PCI.

263 GPI use was 50.5% during UFH PCIs and 12.0% during bivalirudin PCIs.

264 , 53 patients (8.8%) underwent uncomplicated PCI.

265 Patients were randomised 1:1 to undergo PCI or a placebo procedure by use of an automated online

266 All adults undergoing PCI in an outpatient setting were included.

267 Among patients undergoing PCI for myocardial infarction, the rate of the composite

268 All adult patients undergoing PCI in 93 English and Welsh NHS hospitals between 2007 a

269 between black and white patients undergoing PCI in the VA health system.

270 h 1-year mortality among patients undergoing PCI in VA hospitals.

271 e randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold

272 ohort of 453 475 elderly patients undergoing PCI, 39 850 developed AKI (8.8% overall; AKIN stage 1, 8

273 ort of a trial involving patients undergoing PCI, there was no significant difference in the rate of

274 ntagonist, cangrelor, in patients undergoing PCI.

275 f US kidney transplant recipients undergoing PCI, DES was associated with better clinical outcomes be

276 in patients with low DAPT scores undergoing PCI but reduced risk for ischemic events in patients wit

277 I) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y12 inhibito

278 ed 19 047 patients, of whom 18 306 underwent PCI and were included in the primary analysis.

279 as lower among those who initially underwent PCI of the culprit lesion only than among those who unde

280 Forty-five patients underwent PCI with stenting, of whom 41 had sustained angina sympt

281 alyzed all randomized patients who underwent PCI and received the study drug (n = 24,902).

282 245 kidney transplant patients who underwent PCI between April 2003 and December 2010; 2400 and 845 p

283 pared black and white patients who underwent PCI between October 1, 2007, and September 30, 2013, at

284 ants included 1349612 patients who underwent PCI performed by 5973 physicians in 1338 hospitals betwe

285 erwent CABG and 1,863 patients who underwent PCI were included.

286 METHODS AND In a 10-site US PCI registry, we assessed angina before and at 1, 6, and

287 tine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI]) enrolled 19 047 patie

288 mpact of mode of revascularization (CABG vs. PCI with drug-eluting stents) in diabetic patients with

289 However, when PCI with a low SYNTAX score was compared with CABG with

290 sion had similar outcomes than TAVR in which PCI was not performed.

291 ssel coronary artery disease in a child with PCI with BRS implantation.

292 ies, CABG seems more favorable compared with PCI in this particular clinical setting.

293 When compared with PCI, CABG still showed a survival benefit (hazard ratio,

294 disease may benefit from CABG compared with PCI.

295 patients taken to the nearest hospital with PCI center status (odds ratio, 3.07; 95% confidence inte

296 Of the 112 691 patients with PCI, 67 442 (59.8%) underwent at least 1 stress test, wi

297 lthough a greater early benefit is seen with PCI.

298 rial of Routine Aspiration Thrombectomy With PCI Versus PCI Alone in Patients With STEMI]) enrolled 1

299 18.3% (319 events) in patients treated with PCI and 16.9% (292 events) in patients treated with CABG

300 s did not differ in patients with or without PCI or in those with a diagnosis of ST-segment elevation